Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer

doi:10.3748/wjg.v26.i16.1912

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8976)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

466

WORD

215

HTML

5117

Figures (1-3)

380

Tables (1-5)

282

Sum=6460

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

867

Download

1649

Sum=2516

Apr 28, 2020 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Apr 28, 2020; 26(16): 1912-1925
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1912

Table 1 Local gene expression of pro and anti-inflammatory cytokines in paired inflamed vs non-inflamed tissues of inflammatory bowel disease patients and paired tumoral vs adjacent non-tumoral mucosa of colorectal cancer patients

Genes	IBD			CRC			P value IBD vs CRC
	dCt ± SD		RQ (min-max)	dCt ± SD		RQ (min-max)
	Inflamed tissue	Non-inflamed tissue	RQ (min-max)	Tumoral tissue	Non-tumoral tissue	RQ (min-max)
Foxp3	14.94 ± 2.65	15.81 ± 2.59	1.82 (0.11-74.85)	18.62 ± 5.5	21.30 ± 4.3	6.42 (0.47-97.2)	0.025
TGFB1	9.52 ± 4.13	8.97 ± 4.4	0.68 (0.03-2.27)	17.27 ± 2.9	18.63 ± 1.9	2.37 (0.211-93.7)	0.007
IL-10	16.87 ± 1.76	17.7 ± 1.5	1.78 (0.22-28.5)	16.43 ± 5.5	19.17 ± 4.4	6.66 (0.43-202.3)	0.023
IL-6	17.13 ± 3.05	19.53 ± 2.7	5.28 (0.27-61.6)	19.11 ± 3.8	21.07 ± 2.5	3.88 (0.03-512.4)	0.784
IL-23A	18.0 ± 2.09	18.1 ± 2.8	1.07 (0.07-6.61)	12.56 ± 2.1	17.55 ± 2.5	28.5 (2.04-219.5)	0.0003
IL-17A	18.9 ± 2.65	20.3 ± 2.9	2.70 (0.07-20.5)	24.7 ± 4.3	26.9 ± 3.0	4.69 (0.034-494.9)	0.574

The results are presented as dCt ± SD and RQ (min-max). IBD: Inflammatory bowel disease; CRC: Colorectal cancer; dCt: Normalized to the endogenous control; RQ: Relative quantity of mRNA levels.

Table 2 The local gene expression in inflammatory bowel disease patients compared to that in early colorectal cancer cases

Genes	IBD			Early stages CRC (1 + 2)			P value IBD vs Early CRC
	dCt ± SD		RQ (min-max)	dCt ± SD		RQ (min-max)
	Inflamed tissue	Non-inflamed tissue	RQ (min-max)	Tumoral tissue	Non-tumoral tissue	RQ (min-max)
Foxp3	14.94 ± 2.65	15.81 ± 2.59	1.82 (0.11-74.85)	16.98 ± 5.8	20.41 ± 4.5	10.74 (0.615-97.2)	0.023
TGFB1	9.52 ± 4.13	8.97 ± 4.4	0.68 (0.03-2.27)	16.99 ± 2.4	18.83 ± 2.3	3.59 (0.222-93.7)	0.057
IL-10	16.87 ± 1.76	17.7 ± 1.5	1.78 (0.22-28.5)	16.17 ± 5	19.25 ± 4.1	8.44 (1.253-202.3)	0.019
IL-6	17.13 ± 3.05	19.53 ± 2.7	5.28 (0.27-61.6)	18.12 ± 4.7	20.59 ± 1.9	5.55 (0.03-512.4)	0.97
IL-23A	18.0 ± 2.09	18.1 ± 2.8	1.07 (0.07-6.61)	11.69 ± 1.9	17.65 ± 2.9	61.93 (2.04-219.5)	0.001
IL-17A	18.9 ± 2.65	20.3 ± 2.9	2.70 (0.07-20.5)	22.42 ± 3.6	27.17 ± 2.9	26.83 (2.73-494.9)	0.029

The results are presented as dCt ± SD and RQ (min-max). IBD: Inflammatory bowel disease; CRC: Colorectal cancer; dCt: Normalized to the endogenous control; RQ: Relative quantity of mRNA levels.

Table 3 The local gene expression in inflammatory bowel disease patients compared to that in advanced colorectal cancer cases

Genes	IBD			Advanced stages CRC (3 + 4)			P value IBD vs Advanced CRC
	dCt ± SD		RQ (min-max)	dCt ± SD		RQ (min-max)
	Inflamed tissue	Non-inflamed tissue	RQ (min-max)	Tumoral tissue	Non-tumoral tissue	RQ (min-max)
Foxp3	14.94 ± 2.65	15.81 ± 2.59	1.82 (0.11-74.85)	19.71 ± 5.2	21.89 ± 4.2	4.55 (0.45-45.1)	0.101
TGFB1	9.52 ± 4.13	8.97 ± 4.4	0.68 (0.03-2.27)	17.46 ± 3.3	18.5 ± 1.6	2.05 (0.211-14.56)	0.176
IL-10	16.87 ± 1.76	17.7 ± 1.5	1.78 (0.22-28.5)	16.69 ± 6.2	19.09 ± 5	5.26 (0.43-158.8)	0.113
IL-6	17.13 ± 3.05	19.53 ± 2.7	5.28 (0.27-61.6)	19.78 ± 3.1	21.39 ± 2.8	3.05 (0.025-434.7)	0.608
IL-23A	18.0 ± 2.09	18.1 ± 2.8	1.07 (0.07-6.61)	13.64 ± 2.1	17.44 ± 2.4	13.96 (3.93-36.28)	0.012
IL-17A	18.9 ± 2.65	20.3 ± 2.9	2.70 (0.07-20.5)	26.62 ± 3.9	26.73 ± 3.2	1.07 (0.034-89.26)	0.350

The results are presented as dCt ± SD and RQ (min-max). IBD: Inflammatory bowel disease; CRC: Colorectal cancer; dCt: Normalized to the endogenous control; RQ: Relative quantity of mRNA levels.

Table 4 Serum levels of pro and anti-inflammatory cytokines in inflammatory bowel disease and colorectal cancer patients

Cytokines	IBD patients	CRC patients	P value (U-test)
TGFB1 (ng/mL)	11.19 (9.36-20.99)	22.57 (18.08-29.65)	0.0008
IL-10 (pg/mL)	0.4 (0.0-2.8)	8.29 (6.75-15.12)	0.000001
IL-6 (pg/mL)	0.0 (0.0-2.7)	3.21 (2.03-4.19)	0.012
IL-23A (pg/mL)	0.7 (0.0-3.7)	27.55 (25.35-33.0)	0.000001
IL-17A (pg/mL)	0.0 (0.0-0.26)	2.85 (0.0-9.0)	0.034

The results are presented as median (IQR: 25%-75% percentile). IBD: Inflammatory bowel disease; CRC: Colorectal cancer.

Table 5 Serum levels of anti and pro-inflammatory cytokines in inflammatory bowel disease patients compared to early and advanced colorectal cancer cases

Cytokines	IBD	Early CRC	P value (U-test), IBD vs early CRC	Advanced CRC	P value (U-test), IBD vs advanced CRC
TGFB1 (ng/mL)	11.19 (9.36-20.99)	22.74 (18.17-27.98)	0.001344	21.51 (15.5-31.05)	0.0031
IL-10 (pg/mL)	0.4 (0.0-2.8)	7.73 (6.0-12.71)	0.000006	8.84 (7.2-19.81)	0.000002
IL-6 (pg/mL)	0.0 (0.0-2.7)	3.06 (2.03-4.19)	0.0153	4.19 (2.15-8.4)	0.044
IL-23A (pg/mL)	0.7 (0.0-3.7)	25.7 (24.6-32.5)	0.000024	30.5 (26.3-33.5)	0.000009
IL-17A (pg/mL)	0.0 (0.0-0.26)	3.62 (0.0-8.23)	0.0086	1.2 (0.0-12.08)	0.178

The results are presented as median (IQR, 25%-75% percentile). IBD: Inflammatory bowel disease; CRC: Colorectal cancer.

Citation: Velikova TV, Miteva L, Stanilov N, Spassova Z, Stanilova SA. Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer. World J Gastroenterol 2020; 26(16): 1912-1925
URL: https://www.wjgnet.com/1007-9327/full/v26/i16/1912.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i16.1912